🩸 Plasma Amyloid Beta Ratio Diagnostic Simulator

Amyloid-Beta 42 and 40 — Two Peptide Isoforms, One Diagnostic Signal

Short placeholder: Aβ42 and Aβ40 differ by two C-terminal residues.

• 42 aa: Aβ42 length (Placeholder isoform note)
• 40 aa: Aβ40 length (Placeholder isoform note)
• Aβ42↑: Aggregation bias (Placeholder aggregation note)
• Aβ40>Aβ42: Plasma abundance (Placeholder abundance note)

Peptide isoform biology placeholder

Short placeholder describing APP cleavage generating Aβ42 and Aβ40 isoforms.

Correlating Plasma Biomarkers with CSF and Amyloid PET Findings

Short placeholder: plasma ratio tracks CSF and PET amyloid status.

• ~85%: Plasma-PET concordance (Placeholder concordance note)
• Strong: CSF correlation (Placeholder correlation note)
• EDTA plasma: Sample type (Placeholder sample note)
• Multiple: Preanalytical factors (Placeholder handling note)

Cross-modality correlation placeholder

Short placeholder on plasma versus CSF/PET biomarker concordance.

Calculating the Aβ42/40 Ratio — Methodology Overview

Short placeholder: ratio computed by dividing Aβ42 by Aβ40 concentration.

• 42/40: Formula (Placeholder formula note)
• pg/mL: Units (Placeholder units note)
• Internal std: Normalization (Placeholder normalization note)
• CV<10%: Assay precision (Placeholder precision note)

Ratio derivation placeholder

Short placeholder describing analytical steps for ratio calculation.

Diagnostic Cutoff Values and Clinical Interpretation

Short placeholder: cutoff thresholds classify amyloid pathology risk.

• >0.095: Normal cutoff (Placeholder cutoff note)
• <0.080: Abnormal cutoff (Placeholder cutoff note)
• 0.080–0.095: Borderline zone (Placeholder zone note)
• Screening: Clinical use (Placeholder use-case note)

Cutoff interpretation placeholder

Short placeholder on interpreting ratio values against diagnostic cutoffs.

Mass Spectrometry vs Immunoassay Detection Platforms

Short placeholder: platform choice affects sensitivity and precision.

• High: Mass spec precision (Placeholder platform note)
• High: Immunoassay throughput (Placeholder platform note)
• MS higher: Cost comparison (Placeholder cost note)
• Growing: Clinical adoption (Placeholder adoption note)

Platform comparison placeholder

Short placeholder comparing mass spectrometry and immunoassay platforms.

Placeholder key insight on platform selection for clinical labs.